Kyowa Kirin International plc.
Patricia Fisken has a varied and extensive work experience. Patricia currently holds the position of Head - New Product Planning, Global Product Strategy at Kyowa Kirin International plc. which they began in January 2022. Prior to this, they served as the EMEA Franchise Head - Neurology from May 2021 to January 2022. From June 2020 to May 2021, they were the Northern Cluster Business Franchise Lead - Rare Disease BU. Patricia also worked as the Rare Disease Business Unit Director from January 2018 to June 2020 and as a Marketing Manager from May 2016 to January 2018 at Kyowa Kirin International plc.
Before joining Kyowa Kirin International plc., Patricia worked at Novo Nordisk. Patricia held the position of Senior Global Project Lead - Life Cycle Management from March 2014 to April 2016 and served as the Haemophilia / Rare Bleeding Disorders Senior Marketing Manager from July 2010 to March 2014.
Earlier in their career, Patricia worked at So What? Research as the Director - Strategic Market Research from September 2007 to July 2010. Patricia also worked at GENACTIS LTD as the Strategic Account Director from June 2003 to January 2006 and at NFO Healthcare as the Strategic Account Director from January 2002 to May 2003.
Patricia started their career at PwC Australia as a Principle Consultant from June 2000 to December 2001.
Patricia Fisken holds a Master of Business Administration (MBA) in Business Administration and Management from The University of Edinburgh. Patricia also has a Bachelor of Science (BSc Hons) in Genetics from the School of Biological Sciences, University of Aberdeen.
This person is not in any offices
Kyowa Kirin International plc.
At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East. KKI, headquartered in Marlow, England, and Galashiels, Scotland, is owned by Kyowa Kirin Co., Ltd (KKC), of Japan. Founded in 1949, KKC has a successful track record in Japan and has expanded globally. Our history of innovation is built on a strong legacy of scientific discovery and fostering collaborations that accelerate the delivery of innovative medicines to patients. Grounded in our expertise in antibody engineering, we continue to investigate new molecules with the potential to contribute to the future of healthcare and make a difference in the lives of patients. At KKI, it is our people who have helped make a real difference to our success. Working together, our employees excel in achieving results quickly and effectively, bringing diverse and unique viewpoints to the company to achieve our vision. Our passion and energy around our core values of commitment to life, innovation, integrity and teamwork help ensure that every day, each of us is focused on not just making medicines, but also making people smile. With our strong legacy and exciting future, KKI is looking for great people to join our team and support our commitment to life.